Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 681-692

  Witzig, Thomas E ^a   Timm, Michael ^a   Stenson, Mary ^a   Svingen, Phyllis A ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ARYLBUTYRIC ACID DERIVATIVE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PHENYLACETIC ACID; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA DEGRADATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; PHENYLACETATES; PHENYLBUTYRATES; TUMOR CELLS, CULTURED;

EID: 0033952555     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Mendenhall, C., Rouster, S., Marshall, L., and Weesner, R. A new therapy for portal systemic encephalopathy. Am. J. Gastroenterol., 81: 540-543, 1986.
2. Brusilow, S., Tinker, J., and Batshaw, M. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science (Washington DC), 207: 659-661, 1980.
3. Brusilow, S., Danney, M., Waber, L., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C., and Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med., 310: 1630-1634, 1984.
4. Brusilow, S. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res., 29: 147-150, 1991.
5. Samid, D., Shack, S., and Sherman, L. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
6. Wang, J., Saunthararajah, Y., Redner, R., and Liu, J. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res., 59: 2766-2769, 1999.
7. Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
8. Engelhard, H. H., Homer, R. J., Duncan, H. A., and Rozental, J. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J. Neuro-oncol., 37: 97-108, 1998.
9. Ram, Z., Samid, D., Walbridge, S., Oshiro, E., Viola, J., Tao-Cheng, J-H., Shack, S., Thibault, A., Myers, C., and Oldfield, E. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res., 54: 2923-2927, 1994.
10. Carducci, M., Nelson, J., Chan-Tack, K., Ayyagari, S., Sweatt, W., Campbell, P., Nelson, W., and Simons, J. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
11. Gore, S. D., Samid, D., and Weng, L. J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res., 3: 1755-1762, 1997.
12. Huang, Y., and Waxman, S. Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin. Cancer Res., 4: 2503-2509, 1998.
13. Castillo, M., Martinez-Cayuela, M., Zafra, M., and Garcia-Peregrin, E. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterolgenesis. Mol. Cell. Biochem., 105: 21-25, 1991.
14. Pineau, T., Hudgins, W. R., Liu, L., Chen, L. C., Sher, T., Gonzalez, F. J., and Samid, D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.
15. Marshall, C. Protein prenylation: a mediator of protein-protein interactions. Science (Washington DC), 259: 1865-1866, 1993.
16. Hudgins, W. R., Shack, S., Myers, C. E., and Samid, D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem. Pharmacol., 50: 1273-1279, 1995.
17. Danesi, R., Nardini, D., Basolo, F., Del Tacca, M., Samid, D., and Myers, C. E. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol. Pharmacol., 49: 972-979, 1996.
18. Shack, S., Chen, L. C., Miller, A. C., Danesi, R., and Samid, D. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int. J. Cancer, 63: 124-129, 1995.
19. Adam, L., Crepin, M., Savin, C., and Israel, L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res., 55: 5156-5160, 1995.
20. Adam, L., Crepin, M., and Israel, L. Tumor growth inhibition, apoptosis, and bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res., 57: 1023-1029, 1997.
21. Gorospe, M., Shack, S., Guyton, K. Z., Samid, D., and Holbrook, N. J. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ., 7: 1609-1615, 1996.
22. Dover, G., Brusilow, S., and Samid, D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N. Engl. J. Med., 327: 569-570, 1992.
23. Dover, G. J., Brusilow, S., and Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood, 84: 339-343, 1994.
24. Perrine, S., Cinder, G., Faller, D., Dover, G., Ikuta, T., Witkowska, H., Cai, S-P., Vichinsky, E., and Olivieri, N. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N. Engl. J. Med., 328: 81-86, 1993.
25. Sher, G., Ginder, G., Little, J., Yang, S., Dover, G., and Olivieri, N. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N. Engl. J. Med., 332: 1606-1610, 1995.
26. Rubenstein, R. C., and Zeitlin, P. L. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in 8F508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med., 757: 484-490, 1998.
27. Shack, S., Miller, A., Liu, L., Prasanna, P., Thibault, A., and Samid, D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.
28. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, A. O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D., and Myers, C. E. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
29. Piscitelli, S. C., Thibault, A., Figg, W. D., Tompkins, A., Headlee, D., Lieberman, R., Samid, D., and Myers, C. E. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J. Clin. Pharmacol., 35: 368-373, 1995.
30. Witzig, T., Banks, P., Stenson, M., Greipp, P., Katzmann, J., Habermann, T., Colgan, J., and Gonchoroff, N. Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. Am. J. Clin. Pathol., 94: 280-286, 1990.
31. Hendricks, C., Rowinsky, E., Grochow, L., Donehower, R., and Kaufmann, S. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
32. Kirkpatrick, D., Duke, M., and Goh, T. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk. Res., 14: 459-466, 1990.
33. Jelinek, D., Witzig, T., and Arendt, B. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J. Immunol., 159: 487-496, 1997.
34. Philpott, N., Turner, A., Scopes, J., Westby, M., Marsh, J., Gordon-Smith, E., Dalgleish, A., and Gibson, F. The use of 7-aminoactinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood, 87: 2244-2251, 1996.
35. Kaufmann, S. H. Additional members of the rat liver lamin polypeptide family. Structural and immunological characterization. J. Biol. Chem., 264: 13946-13955, 1989.
36. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
37. Martins, L. M., Kottke, T., Mesner, P. W., Basi, G. S., Sinha, S., Frigon, N., Jr., Tatar, E., Tung, J. S., Bryant, K., Takahashi, A., Svingen, P. A., Madden, B. J., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. J. Biol. Chem., 272: 7421-7430, 1997.
38. Mesner P., Jr., Bible, K., Martins, L., Kottke, T., Srinivasula, S., Svingen, P., Chilcote, T., Basi, G., Tung, J., Karjewski, S., Reed, J., Alnemri, E., Earnshaw, E., and Kaufmann, S. Caspase processing and activation in HL-60 cell cytosol under cell-free conditions: nucleotide requirement and inhibitor profile. J. Biol. Chem., 274: 22635-22645, 1999.
39. Bible, K., and Kaufmann, S. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
40. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effective relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
41. Collins, A. F., Pearson, H. A., Giardina, P., McDonagh, K. T., Brusilow, S. W., and Dover, G. J. Oral sodium phenylbutyrate therapy in homozygous β thalassemia: a clinical trial. Blood, 85: 43-49, 1995.
42. Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N., Headlee, D. J., Kohler, D. R., Venzon, D. J., and Myers, C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2932-2938, 1995.
43. Chang, S. M., Kuhn, J. G., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Schiff, D., Gilbert, M., Rankin, C., and Prados, M. D. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol., 77: 984-990, 1999.
44. Earnshaw, W., Martins, L., and Kaufmann, S. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu. Rev. Biochem., 68: 383-424, 1999.
45. Thornberry, N. A., and Lazebnik, Y. Caspases: enemies within. Science (Washington DC), 281: 1312-1316, 1998.
46. Takahashi, A., Alnemri, E. S., Lazebnik, Y. A., Fernandes-Alnemri, T., Litwack, G., Moir, R. D., Goldman, R. D., Poirier, G. G., Kaufmann, S. H., and Earnshaw, W. C. Cleavage of lamin A by Mch2 α but not CPP32: multiple interleukin 1 β-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc. Natl. Acad. Sci. USA, 93: 8395-8400, 1996.
47. Samejima, K., Svingen, P. A., Basi, G. S., Kottke, T., Mesner, P. W., Jr., Stewart, L., Durrieu, F., Poirier, G. G., Alnemri, E. S., Champoux, J. J., Kaufmann, S. H., and Earnshaw, W. C. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J. Biol. Chem., 274: 4335-4340, 1999.
48. Kaufmann, S., Peereboom, D., Buckwalter, C., Svingen, P., Grochow, L., Donehower, R., and Rowinsky, E. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst., 88: 734-741, 1996.
49. Maestri, N. E., Brusilow, S. W., Clissold, D. B., and Bassett, S. S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med., 335: 855-859, 1996.
50. Samid, D., Yeh, T-J., and Shack, S. Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFNα activity in vitro. Br. J. Haematol., 79 (Suppl 1): 81-83, 1991.
51. Figg, W. D., Walls, R. G., Cooper, M. R., Thibault, A., Sartor, O., McCall, N. A., Myers, C. E., and Samid, D. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs, 5: 336-342, 1994.
52. Goto, I., Yamamoto-Yamaguchi, Y., and Honma, Y. Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon α by differentiation-inducing agents. Br. J. Cancer, 74: 546-554, 1996.
53. Sidell, N., Wada, R., Han, G., Chang, B., Shack, S., Moore, T., and Samid, D. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer, 60: 507-514, 1995.
54. Sidell, N., Chang, B., Yamashiro, J. M., and Wada, R. K. Transcriptional up-regulation of retinoic acid receptor β (RAR β) expression by phenylacetate in human neuroblastoma cells. Exp. Cell Res., 239: 169-174, 1998.
55. Pelidis, M. A., Carducci, M. A., and Simons, J. W. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int. J. Oncol., 12: 889-893, 1998.
56. Ferrandina, G., Melichar, B., Loercher, A., Verschraegen, C. F., Kudelka, A. P., Edwards, C. L., Scambia, G., Kavanagh, J. J., Abbruzzese, J. L., and Freedman, R. S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res., 57: 4309-4315, 1997.
57. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
58. Warrell, R. P., Jr., He, L. Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.
59. Greene, R. F., Collins, J. M., Jenkins, J. F., Speyer, J. L., and Myers, C. E. Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res., 43: 3417-3421, 1983.
60. Speth, P. A., Linssen, P. C., Holdrinet, R. S., and Haanen, C. Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin. Pharmacol. Ther., 41: 661-665, 1987.
61. Bronchud, M. H., Margison, J. M., Howell, A., Lind, M., Lucas, S. B., and Wilkinson, P. M. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother. Pharmacol., 25: 435-439, 1990.
62. Henwood, J. M., and Brogden, R. N. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs, 39: 438-490, 1990.
63. Schiller, J. H., Kim, K., Hutson, P., DeVore, R., Glick, J., Stewart, J., and Johnson, D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol., 14: 2345-2352, 1996.
64. Haas, N. B., LaCreta, F. P., Walczak, J., Hudes, G. R., Brennan, J. M., Ozols, R. F., and O'Dwyer, P. J. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res., 54: 1220-1226, 1994.
65. Early, A. P., Preisler, H. D., Slocum, H., and Rustum, Y. M. A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res., 42: 1587-1594, 1982.
66. Alberts, D. S., Chang, S. Y., Chen, H. S., Larcom, B. J., and Evans, T. L. Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res., 74: 124-131, 1980.
67. Alberts, D. S., Chang, S. Y., Chen, H. S., Larcom, B. J., and Jones, S. E. Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat. Rev., 6: 9-17, 1979.
68. Alberts, D. S., Chang, S. Y., Chen, H. S., Evans, T. L., and Moon, T. E. Oral melphalan kinetics. Clin. Pharmacol. Ther., 26: 737-745, 1979.
69. Alberts, D. S., Chang, S. Y., Chen, H. S., Moon, T. E., Evans, T. L., Furner, R. L., Himmelstein, K., and Gross, J. F. Kinetics of intravenous melphalan. Clin. Pharmacol. Ther., 26: 73-80, 1979.
70. Ross, S. R., McTavish, D., and Faulds, D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs. 45: 737-759, 1993.
71. Gandara, D. R., DeGregorio, M. W., Wold, H., Wilbur, B. J., Kohler, M., Lawrence, H. J., Deisseroth, A. B., and George, C. B. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J. Clin. Oncol., 4: 1787-1793, 1986.
72. Gormley, P. E., Bull, J. M., LeRoy, A. F., and Cysyk, R. Kinetics of cis-dichlorodiammineplatinum. Clin. Pharmacol. Ther., 25: 351-357, 1979.
73. Bajorin, D. F., Bosl, G. J., Alcock, N. W., Niedzwiecki, D., Gallina, E., and Shurgot, B. Pharmacokinetics of cis-diamminedichloroplatmum(II) after administration in hypertonic saline. Cancer Res., 46: 5969-5972, 1986.
74. Oguri, S., Sakakibara, T., Mase, H., Shimizu, T., Ishikawa, K., Kimura, K., and Smyth, R. D. Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol., 28: 208-215, 1988.
75. Rubenstein, R. C., Egan, M. E., and Zeitlin, P. L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing δ F508-CFTR. J. Clin. Invest., 100: 2457-2465, 1997.
76. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a protein-ase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.
77. Scaffidi, C., Medema, J. P., Krammer, P. H., and Peter, M. E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem., 272: 26953-26958, 1997.